熱門資訊> 正文
Zymeworks加入花旗催化剂手表后上涨
2026-08-11 00:05
- Zymeworks (ZYME) is up ~2% in Monday trading after Citi added the stock to its 90-day catalyst watch list.
- The bank sees shares rising due to an August 25 FDA action date for zanidatamab, sold as Ziihera, as a first-line treatment for gastroesophageal adenocarcinoma. The drug is sold by Jazz Pharmaceuticals (JAZZ).
- Ziihera was approved as a second-line treatment under accelerated approval in 2024.
- Analyst Yigal Nochomovitz sees approval derisked considering results from the HERIZON-GEA-01 trial.
- "Approval would trigger a $250M U.S. milestone and begin unlocking the broader $440M global GEA milestone opportunity, while supporting a larger Ziihera royalty base over time," he added.
More on Zymeworks
- A Post Acquisition Look At Zymeworks
- Here's Why Zymeworks Inc. Paid $929 Million For Theravance Biopharma
- Zymeworks Inc. (ZYME) M&A Call - Slideshow
- Zymeworks Q2 2026 Earnings Preview
- Zymeworks to pay $17/share for Theravance Biopharma in $929M deal
推薦文章
華盛早報 | 美聯儲鷹派加息「嚇壞」美股！沃什再度拒絕給出點陣圖；OpenAI提議設立AI安全報告機制；NEBIUS上調英偉達GPU租賃價
今夜加息概率升破92%！全球風暴即將來襲？覆盤近三輪加息周期，這次會走2015還是2022年劇本？
5%美債收益率風暴來襲！再融資炸彈倒計時開啟，誰會是第一個犧牲品？
美參議院加密市場結構法案程序性投票未獲通過 兩黨談判破裂致立法進程受阻
利率決議前夕黃金「搶跑」！美聯儲兩難困境正被看穿：加息是利空出盡，不加息金價衝5000？
扎克伯格稱更青睞依靠評估人員確保AI安全 而非放緩發展
攜程2026Q2淨利潤同比下降，受處罰費用影響，錄得淨虧損24億元！
加密貨幣法案折戟美國參議院！比特幣、以太幣跌至6月來最低
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
